What is the recommended treatment for community-acquired pneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Community-Acquired Pneumonia

For community-acquired pneumonia (CAP), the recommended first-line treatment is a combination of ceftriaxone (1-2 g/day) with a macrolide (preferably azithromycin) for hospitalized patients, or a respiratory fluoroquinolone like levofloxacin for outpatients or those with specific pathogens. 1

Empiric Treatment Based on Setting and Severity

Outpatient Treatment

  • Mild to moderate CAP without comorbidities:

    • Amoxicillin or
    • Macrolide (azithromycin 500mg on day 1, then 250mg daily for days 2-5) 2
    • Consider doxycycline if atypical pathogens are suspected
  • Outpatient with comorbidities or risk factors:

    • Respiratory fluoroquinolone (levofloxacin 750mg daily for 5 days) 3 or
    • Beta-lactam plus macrolide combination

Inpatient (Non-ICU) Treatment

  • Preferred regimen: Ceftriaxone (1-2g/day) plus azithromycin 1
  • Alternative: Respiratory fluoroquinolone monotherapy (levofloxacin 750mg daily) 3

ICU Treatment

  • Preferred regimen: Ceftriaxone combined with either a macrolide or a respiratory fluoroquinolone 1
  • If Pseudomonas suspected: Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin/levofloxacin or an aminoglycoside plus azithromycin 1
  • If MRSA suspected: Add vancomycin or linezolid to standard therapy 1

Pathogen-Specific Treatment

Pathogen Recommended Treatment
Streptococcus pneumoniae Beta-lactams (amoxicillin, ceftriaxone) [1]
Mycoplasma pneumoniae Macrolide (azithromycin preferred) [1]
Legionella spp. Levofloxacin (preferred), moxifloxacin, or macrolide ± rifampicin [1]
Chlamydophila pneumoniae Doxycycline, macrolide, levofloxacin, or moxifloxacin [1]
Pseudomonas aeruginosa Antipseudomonal beta-lactam plus either fluoroquinolone or aminoglycoside [1]

Treatment Duration

  • Standard uncomplicated CAP: Minimum 5 days when clinical stability is achieved 1
  • CAP caused by MRSA or Pseudomonas: 7 days recommended 1
  • Levofloxacin high-dose regimen: 750mg daily for 5 days 3
  • Azithromycin regimen: 500mg on day 1, then 250mg daily for days 2-5 2

Monitoring and Response Assessment

  • Fever should resolve within 2-3 days after starting antibiotics 1
  • Treatment failure is indicated by:
    • Persistent fever beyond 3 days
    • Worsening respiratory symptoms
    • Progression of pulmonary infiltrates 1
  • Maintain SaO₂ >92% in uncomplicated cases with oxygen supplementation 1
  • Monitor vital signs, mental status, and oxygen saturation at least twice daily 1

Switching from IV to Oral Therapy

Switch from IV to oral therapy when patient:

  • Is hemodynamically stable
  • Shows clinical improvement
  • Can ingest medications
  • Has a normally functioning gastrointestinal tract 1

Common Pitfalls to Avoid

  • Inadequate initial coverage: Ensure empiric therapy covers both typical and atypical pathogens
  • Delayed switch from IV to oral: Transition promptly when criteria are met
  • Inappropriate duration: Avoid extending treatment beyond recommended duration when patient has achieved clinical stability
  • Failure to recognize treatment failure: Reassess if no improvement after 72 hours
  • Overuse of antibiotics: Use narrow-spectrum antibiotics when a pathogen is identified 1

Recent evidence suggests that early administration of systemic corticosteroids (within 24 hours) may reduce mortality in severe CAP 4, though this should be considered on a case-by-case basis.

References

Guideline

Community-Acquired Pneumonia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.